Document Detail


Longitudinal analysis of mammary cancer multiplicity in chemoprevention studies.
MedLine Citation:
PMID:  10953286     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The effect of chemopreventive agents on cancer multiplicity is of primary interest in animal studies. The nature of data collected from chemoprevention studies may be analyzed by a longitudinal analysis of repeatedly measured cancer multiplicity data. METHODS: We determined the number of mammary cancers over the entire follow-up period for varying doses of two chemopreventive agents. Longitudinal analyses were performed to model the number of cancers over different time intervals. RESULTS: There was a significant increase in the number of cancers between six to seven weeks post-carcinogen administration in the control group. Varying patterns of cancer development were observed at different doses of chemopreventive agents including a delay in onset of tumor growth compared to the control group. CONCLUSION: Longitudinal data analysis complements traditional analyses by providing detailed information regarding the effect of chemopreventive agents on the pattern of tumor development throughout the follow-up period. Importantly, some chemopreventive agents may delay time to appearance of mammary cancers without causing a significant difference in cancer multiplicity.
Authors:
H L Weiss; C Rodríguez-Burford; C J Grubbs; W E Grizzle
Related Documents :
10337716 - Chemoprevention of head and neck and lung (pre)cancer.
15849286 - Craniomaxillofacial injury in sport: a review of prevention research.
8985016 - Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.
11569936 - Retinoids for the treatment of psoriasis: outlook for the future.
2564456 - Increased risk of breast cancer after low-dose irradiation.
23224326 - Risk factors for young-onset colorectal cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  20     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2000 Jul-Aug
Date Detail:
Created Date:  2000-08-31     Completed Date:  2000-08-31     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  2281-7     Citation Subset:  IM    
Affiliation:
Biostatistics Unit, University of Alabama at Birmingham 35294, USA. hlweiss@uab.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticarcinogenic Agents / pharmacology*
Female
Mammary Neoplasms, Experimental / pathology,  prevention & control*
Rats
Rats, Sprague-Dawley
Time Factors
Triazoles / pharmacology
Vitamin A / analogs & derivatives,  pharmacology
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Triazoles; 11103-57-4/Vitamin A; 118949-22-7/vorozole; 1224-78-8/anhydrovitamin A; 127-47-9/retinol acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential response of normal, premalignant and malignant human oral epithelial cells to growth in...
Next Document:  Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and ...